Mucosal Inflammation in Children With OSA
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 131 people enrolled
- Started
- 1 Jan 2023
- Ended
- 30 Jun 2026
- Type of study
- Observational, 2 groups
- Record updated
- 23 October 2026
Who can take part
- Age
- 6 years to 11 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- Children aged 6-11 years old
Who cannot take part
- Previous upper airway surgery, genetic or syndromal disease, congenital or acquired neuromuscular disease, suspected or confirmed congenital or acquired immunodeficiency, obesity (BMI z-score ≥1.645), known metabolic syndrome, craniofacial abnormalities, structural or congenital heart disease, use of medications or therapy that could affect immunity such as systemic corticosteroids, chemotherapy, radiation therapy, intravenous immunoglobulins
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Objectives: Variability of clinical phenotypes in childhood obstructive sleep apnoea (OSA) has prompted research for biomarkers to identify patients at risk of developing OSA-related complications. Upper airway inflammation is documented in children with OSA. Whether it is related to end-organ morbidities and systemic inflammation is under-explored. The primary objectives of our study are 1)To evaluate inflammatory biomarkers with the use of nasal epithelial lining fluid (NELF) collected by nasal strips as a representation of upper airway inflammation in children with OSA compared to non-OSA controls; 2) To evaluate the associations between NELF biomarkers with ambulatory blood pressure (ABP) outcomes in children with OSA.
Read full original descriptionShow less
Hypothesis to be tested: Inflammatory biomarkers in NELF in children with OSA are altered when compared with non-OSA controls and correlated with ABP outcomes.
Design and subjects: A prospective case-control study. Non-obese Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (PSG) confirmed OSA (OAHI of ≥1/hour) will be recruited as cases. Non-OSA children with OAHI < 1 event/h will be recruited as controls. All subjects will undergo evaluation including questionnaires, anthropometric measurements, PSG, 24-hour ABP measurement, blood and NELF sampling.
Primary outcome measure: Profile of inflammatory biomarkers in the NELF. Analysis: Correlations between NELF inflammatory biomarkers with polysomnographic and ABP measurements will be evaluated by regression analysis.
Expected results: This study will provide novel and important information regarding upper airway inflammatory biomarkers in children with OSA and their relationship with blood pressure outcomes.
The 2 groups in the trial
- Cases
Children aged 6-11 years old with habitual snoring (≥3 nights per week) and PSG confirmed OSA (OAHI of ≥1/hour)
- Controls
Non-OSA age, sex and BMI-matched control with PSG confirmed absence of OSA (OAHI \< 1 event/h)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mucosal Inflammation in Children With OSA - Potential Biomarkers of OSA Complications
- Record updated
- 23 October 2026